CRSP wyckoff playIt seems CRSP will follow MRNA and the biotech narrative.
According to the technical output, price looks to be developing an LPS, on the D phase, volume decreasing, textbook.
LongCompare with CRISPR Therapeutics AG
Key facts today
−4.76 USD
−581.60 M USD
3.51 M USD
89.79 M
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
Company info
Sector
Industry
CEO
Samarth Kulkarni
Website
Headquarters
Zug
Founded
2013
IPO date
Oct 19, 2016
ISIN
CH0334081137
FIGI
BBG00DBBGRX1
Identifiers
ISIN CH0334081137
CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.
Long
CRISPR: New Downside ScenarioWhat’s Changed?
“Easy come, easy go.” This phrase perfectly sums up CRISPR stock’s price action since our last update. After initially pushing higher, the stock failed to hold its recent gains. Bears quickly regained control, driving the stock down more than 25%. As a result, the stock dropped sign
Short
CRSP Is Shaping Up Nice and CrispNASDAQ:CRSP price has been consolidating in a clean symmetrical triangle since late February, and it's finally broke out of the pattern.
Earlier today, the stock ripped over 11% in just a few minutes, but the broader market weakness pulled it back, creating what I think is a pretty solid dip-buyin
Long
Can $2.44B Save CRISPR From Its Own Patent Adversary?CRISPR Therapeutics enters the second half of 2026 in a paradoxical position. The company sits on $2.44 billion in cash, cash equivalents, and marketable securities after raising $585.4 million in net proceeds from $600 million convertible senior notes due 2031. Q1 2026 results showed a narrowing ne
Long
CRSP Sickle Cell Disease - The Saudis were talking about it YestI have one horse that is just getting started, Did you hear at the Middle East Conference, the host of one of the events was talking about Sickle Cell Disease, remember? Well you know which company has the cure ? CRSP , Crispr Therapeutics, and this is a rocket that will fly, My NPV Valuation today
Long
CRISPR: Downside BiasCRISPR extended its correction over the past few weeks, although the downside momentum has eased somewhat more recently. For now, we primarily expect a sell-off below the support at $30.02. Once a low is established there, the stock should move higher again. Alternatively, the shares could post anot
Short on CRISPR Therapeutics AG (Ticker CRSP)NASDAQ:CRSP
Technicals:
- 5 touches of 59.30 ressitance since 5 Dec. without breakout
- ressistance on 0.382 fibo after breaking to 0.618. Measure since 8 Apr.
- potential downside to 43.00 - 44.50 support zone matching 0.786 fibo
- ыcenario invalidated if two bars close above 61.12
Fundamen
Short
Decoding the Post-Earnings Rally and the Long Road to MaturityCRISPR Therapeutics AG (NASDAQ:CRSP), a pioneer in the field of gene editing, recently saw its stock surge more than 12% following the release of its fourth-quarter 2025 earnings. On the surface, this rally appears counterintuitive. The company reported a net loss that was deeper than analysts had p
Long
CRISPR Therapeutics AG (NASDAQ Market) - 12/1/2026CRISPR Therapeutics AG (NASDAQ Market) - 12/1/2026
5 impulse wave 12345 which is A or 1
Then, zigzag wave ABC which is B or 2
After that, 5 impulse wave 12345 which is C or 3
Regards.
CRSP - Waiting for the PivotCRSP appears headed for a short term decline as it completes the current B Wave. The first reversal opportunity appears to be c. $47. Given that the CFO just sold 80% of his shares (@ $61), there is a reasonable chance the current decline will reach c. $39 before pivoting. This projection is supp
Long
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Maturity dateMar 1, 2031
Coupon1.13% (Fixed)
See all CRSP bonds
Frequently asked questions
The current price of CRSP is 51.83 USD — it has decreased by −1.38% in the past 24 hours. Watch CRISPR Therapeutics AG stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange CRISPR Therapeutics AG stocks are traded under the ticker CRSP.
CRSP stock has fallen by −4.08% compared to the previous week, the month change is a −3.26% fall, over the last year CRISPR Therapeutics AG has showed a −9.47% decrease.
We've gathered analysts' opinions on CRISPR Therapeutics AG future price: according to them, CRSP price has a max estimate of 291.00 USD and a min estimate of 44.00 USD. Watch CRSP chart and read a more detailed CRISPR Therapeutics AG stock forecast: see what analysts think of CRISPR Therapeutics AG and suggest that you do with its stocks.
CRSP reached its all-time high on Jan 15, 2021 with the price of 220.20 USD, and its all-time low was 11.63 USD and was reached on Feb 15, 2017. View more price dynamics on CRSP chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
CRSP stock is 2.85% volatile and has beta coefficient of 1.88. Track CRISPR Therapeutics AG stock price on the chart and check out the list of the most volatile stocks — is CRISPR Therapeutics AG there?
Today CRISPR Therapeutics AG has the market capitalization of 5.12 B, it has decreased by −4.13% over the last week.
Yes, you can track CRISPR Therapeutics AG financials in yearly and quarterly reports right on TradingView.
CRISPR Therapeutics AG is going to release the next earnings report on Nov 4, 2026. Keep track of upcoming events with our Earnings Calendar.
CRSP earnings for the last quarter are −0.94 USD per share, whereas the estimation was −1.19 USD resulting in a 21.31% surprise. The estimated earnings for the next quarter are −1.05 USD per share. See more details about CRISPR Therapeutics AG earnings.
CRISPR Therapeutics AG revenue for the last quarter amounts to 10.18 M USD, despite the estimated figure of 7.45 M USD. In the next quarter, revenue is expected to reach 14.84 M USD.
CRSP net income for the last quarter is −91.15 M USD, while the quarter before that showed −122.93 M USD of net income which accounts for 0.00% change. Track more CRISPR Therapeutics AG financial stats to get the full picture.
No, CRSP doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. CRISPR Therapeutics AG EBITDA is −513.19 M USD, and current EBITDA margin is −15.64 K%. See more stats in CRISPR Therapeutics AG financial statements.
Like other stocks, CRSP shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade CRISPR Therapeutics AG stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So CRISPR Therapeutics AG technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating CRISPR Therapeutics AG stock shows the sell signal. See more of CRISPR Therapeutics AG technicals for a more comprehensive analysis.